Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study

Abstract : Background & AimsTreatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. MethodsGIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1-24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8-25.0 months). ConclusionsData from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.
Document type :
Journal articles
Complete list of metadata
Contributor : NGERE UL Connect in order to contact the contributor
Submitted on : Monday, December 18, 2017 - 2:14:56 PM
Last modification on : Thursday, February 4, 2021 - 2:40:01 PM

Links full text




Masatoshi Kudo, Riccardo Lencioni, Jorge A. Marrero, Alan P. Venook, Jean-Pierre Bronowicki, et al.. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver International, Wiley-Blackwell, 2016, 36 (8), pp.1196 - 1205. ⟨10.1111/liv.13096⟩. ⟨hal-01666490⟩



Record views